Coffee review

Caffeine protects against multiple sclerosis in humans

Published: 2024-06-02 Author: World Gafei
Last Updated: 2024/06/02, Treating multiple sclerosis of the spinal cord is one of the most difficult problems in the medical community. Spinal multiple sclerosis is one of the most common forms of multiple sclerosis.

咖啡因能防止人类脊髓多发性硬化症的疾病

The treatment of multiple sclerosis of the spinal cord is a difficult problem in the medical field. Multiple sclerosis of the spinal cord is one of the most common cases of multiple sclerosis. Therefore, it is very important to treat and prevent multiple sclerosis of spinal cord.

According to reports, US researchers recently found that caffeine can prevent mice from developing diseases similar to multiple sclerosis of the spinal cord in humans. This finding will help to develop new methods for the prevention and treatment of multiple sclerosis of the spinal cord.

Jeffrey Mills of Cornell University in the United States and others have found that mice that consume a certain amount of caffeine (equivalent to six to eight cups of coffee a day) are less likely to develop experimental autoimmune encephalomyelitis. This may be the result of caffeine preventing immune cells from entering the mouse central nervous system.

Experimental autoimmune encephalomyelitis is an animal manifestation of human spinal cord multiple sclerosis, which is an autoimmune disease in which the immune system mistakenly attacks its own body, which can damage the brain and spinal cord nerves.

Previous studies have shown that adenosine plays an important role in the pathogenesis of multiple sclerosis of the spinal cord, so it may be responsible for helping immune cells enter the central nervous system. Adenosine exists widely in the human body and plays an important role in biochemistry, such as transferring energy, promoting sleep and so on.

Adenosine needs to bind to adenosine receptors to affect the central nervous system, and caffeine stimulates the central nervous system largely because it binds to adenosine receptors, the researchers said in a statement. so caffeine can be used to prevent adenosine from working.

Studies in mice have also confirmed that mice are less likely to develop experimental autoimmune encephalomyelitis without adenosine receptors and CD73 enzymes necessary for extracellular synthesis of adenosine. The researchers point out that this finding and the role of caffeine may help promote research based on adenosine in the prevention and treatment of multiple sclerosis of the spinal cord.

Experts from Henan Armed Police Corps Hospital pointed out that the treatment of spinal cord multiple sclerosis can be divided into acute treatment and remission treatment. Acute treatment is generally glucocorticoid, mainly including methylprednisolone, dexamethasone, prednisone, can also use gamma globulin, with some vitamin B group, mainly vitamin B1 and vitamin B12. If you have diabetes, high blood pressure, severe gastrointestinal ulcers, etc., it may aggravate these diseases. Immunosuppressants such as azathioprine and cyclophosphamide can be selected. Interferon can be used in remission to prevent recurrence. If these methods have been used and there is still a recurrence, autologous stem cell transplantation can also be selected.

Stem cell transplantation therapy has the ability of self-replication and can differentiate into early undifferentiated cells that can differentiate into at least one kind of functional cells. under certain conditions, stem cells can differentiate into functional cells in the body and form any type of tissue and organs. that is, it has "plasticity", so it is also called "source cell" and "omnipotent cell".

In fact, in the 1950s, stem cell therapy began to be used in clinic, the most typical is the use of hematopoietic stem cells in the treatment of spinal cord multiple sclerosis. Nowadays, the research of stem cells in the treatment of spinal cord multiple sclerosis has been carried out around the world and was listed as one of the ten most anticipated medical breakthroughs in 2005.

0